// App-Quantinova.ai

TPS1138 : A phase II study of eribulin in patients with HER2-negative, metastatic breast cancer: Evaluation of efficacy, toxicity, and patient-reported outcomes.

Researchers

Presenter

  • Otto Metzger-Filho

Principal Investigators

  • Nancy U. Lin

  • Anita Giobbie-Hurder

  • Harold J. Burstein

  • Erica L. Mayer

  • Steven E. Come

  • Thomas H. Openshaw

  • Bryan P. Schneider

Medical Centers

  • Beth Israel Deaconess Medical Center, Boston, MA

  • Eastern Maine Medical Cancer Care of Maine, Brewer, MEIndiana University Melvin and Bren Simon Cancer Center, Indianapolis, INDana-Farber Cancer Institute, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

  • Breast cancer

  • Peripheral neuropathy

  • Solid malignancies

Biomarkers

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Eribulin

Outcome

  • Unknown

Study Design

  • single arm

  • randomized

Phase

  • II

Study Id's

  • NCT01827787

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved